Angiogenesis. Part II. Modulators regulating neovascularization;Angiogeneza. Cz̧ść II. Czynniki moduluja̧ce proces powstawania nowych naczý krwionośnych

Alergia Astma Immunologia

Volumn 9, Issue 1, 2004, Pages 25-31

  Zielonka, Tadeusz M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Angiogenesis; Inhibitors; Stimulatores

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; CHEMOKINE; ENDOSTATIN; GROWTH FACTOR; HEMOSTATIC AGENT; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; MITOGENIC AGENT; NITRIC OXIDE; PROTEINASE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; CYTOKINE PRODUCTION; HUMAN; INHIBITION KINETICS; MEDICAL RESEARCH; NEOVASCULARIZATION (PATHOLOGY); PROCESS MODEL; REVIEW; RISK FACTOR;

EID: 2942565822     PISSN: 14273101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-268.
2. Carmeliet P, Jaint RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
3. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 1984; 23: 217-225.
4. Pepper MS, Mandriota SJ, Vassalli JD, Orci L, Montesano R. Angiogenesis-regulating cytokines: activities and interactions. Curr Topics Microbiol Immun 1996; 213: 31-67.
5. Ferrara N. Role of vascular endothelial growth factor in regulation of angiogenesis. Kidney Internat 1999; 56: 794-814.
6. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 203-212.
7. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Structure Function 2001; 26: 25-35.
8. Klagsbrun M, Moses MA. Molecular angiogenesis. Chemist Biol 1999; 6: R217-R224.
9. Gleizes PE, Noaillac Depeyre J, Amalric F, Gas N. Basic fibroblast growth factor (FGF-2) internalization through the heparan sulfate proteoglicans- mediated pathway: An ultrastructural approach. Eur J Cell Biol 1995; 66: 47-59.
10. Engelmann GL, Dionne CA, Jaye MC. Acidic fibroblast growth factor and heart development. Role in myocyte proliferation and capillary angiogenesis. Circ Res 1993; 72: 7-19.
11. Norrby K. Basic fibroblast growth factor and de novo mammalian angiogensis. Microvasc Res 1994; 48: 96-113.
12. Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor thyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1992; 135: 185-199.
13. Sato TN, Tozawa Y, Deutsch U i wsp. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie2 in blood vessel formation. Nature (Lond) 1995; 376: 70-74.
14. Dunk C, Shams M, Nijjar S i wsp. Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote and migration during placenta development. Am J Pat 2000; 156: 2185-2199.
15. Vikkula M, Boon L, Mulliken JB, Olsen BR. Molecular basis of vascular anomalies. Trends Cardiovasc Med 1998; 8: 281-292.
16. Maisonpierre PC, Suri C, Jones PF i wsp. Angiopoietin-2, a natural antagonist for Tie2 that distrusts in vivo angiogenesis. Science (Wash DC) 1997; 277: 55-60.
17. Folkman J, Brem H. Angiogenesis and inflammation. w: Inflammation: basic principles and clinical correlates, II wyd. JI Gallin, IM Goldstein, R Snyderman Raven Press Ltd New York 1992: 821-839.
18. Schreiber AB, Winkler ME, Derynnck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250-1253.
19. Pepper MS, Belin D, Montesano R, Orci L, Vassalli JD. Transforming growth factor-beta 1 modulates basic fibroblast growth factor - induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990; 111: 743-755.
20. 3 in angiogenesis. EXS 1997; 79: 361-390.
21. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: The role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998; 50: 197-263.
22. v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103: 1227-1230.
23. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericite loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242-245.
24. Sato N, Beitz JG, Kato J i wsp. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993; 142: 1119-1130.
25. Ishikawa F, Miyazono K, Hellman U. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338: 557-562.
26. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 1999; 103: 47-54.
27. Brooks PC, Silletti S, Schalsach TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
28. Cornelius LA. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998; 271: 1079-1086.
29. Shapiro R, Strydom DJ, Olson KA, Vallee BL. Isolation of angiogenin from normal human plasma. Biochemistry 1987; 26: 5141-46.
30. Persico MG, Vincenti V, diPalma T. Structure, expression and receptor-bilding properties of placenta growth factor. Curr Topics Microbiol Immun 1999; 237: 31-40.
31. Koch AE, Polverini PJ, Kundel SL. Interleukin-8 as macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801.
32. Yuan A, Yang PC, Yu CJ i wsp. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumour angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 2000; 162: 1957-1963.
33. Jackson J, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457-65.
34. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin-6 induces the expression of vascular endothelial growth-factor. J Biol Chem 1996; 271: 736-741.
35. Liebovich SJ, Polverini PJ, Shepard HM, Wiesman DM, Shively V, Nusseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 1987; 329: 630-632.
36. Shima N, Itagaki Y, Nagao M, Yasuda H, Morinaaga T, Higashio K. A fibroblast-derived tumor cytotoxic factor/F-TCT (hepatocyte growth facctor/HGF) has multiple functions in vitro. Cell Biol Int Rep 1991; 15: 397-408.
37. Date K, Matsumoto K, Kubs K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998; 17: 3045-3054.
38. Bussolino F, Wang JM, Defilippi P i wsp. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature (London) 1989; 337: 471-473.
39. 3 integrin expression on endothelial cells. Microvascular Res 2000; 60: 269-270.
40. 165- induced angiogenesis. APMIS 2000; 108: 29-37.
41. diPietro L. Thrombospondin as a regulator of agiogenesis. EXS 1997; 79: 295-314.
42. Rastinejad F, Polverini PJ, Bouck N. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989; 56: 345-355.
43. Browder T, Folkman J, Pirie-Shephard S. The hemostatic system as a regulator of angiogenesis. J Biol Chemistry 2000; 275: 1521-1524.
44. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
45. Holmgren L, O'Reilly S, Folkman J. Dormancy of micrometastases: balanced proliferation and apopotosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-53.
46. O'Reilly MS, Holmgren L, Shing Y i wsp. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
47. Perletti G, Concari P, Giardini R i wsp. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 2000; 60: 1793-1796.
48. Moses MA, Langer R. Troponin I is present in human cartilige and inhibits angiogensis. Proc Natl Acad Sci USA. 1999; 96: 2645-2650.
49. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
50. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998; 91: 3289-99.
51. Gengrinovitch S, Greenberg SM, Cohen T i wsp. Platelet factor-4 inhibits the mitogenic activity of VEGF-121 and VEGF-165 using several concurrent mechanisms J Biol Chem 1995; 270: 15059-65.
52. Majewski S, Szmurlo NA, Marczak M, Jablonska S, Bollag W. Synergistic effect of retinoids and interferon α on tumor-induced angiogenesis: antiangiogenic effect on HPV-harboring tumor cell lines. Int J Cancer 1994; 57: 81-85.
53. Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem. 1994; 55: 419-434.
54. Friesel R, Komoriya A, Macia̧g T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987; 104: 689-696.
55. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 1999; 19: 697-703.
56. Silvestre JS, Mallat Z, Duriez M i wsp. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ Res 2000; 87: 448-452.
57. Voest E, Kenyon BM, O'Reilly M, Truitt G, D'Amato R, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J National Cancer Inst 1995; 87: 581-586.
58. Duda DG, Sunamura M, Lozonschi L i wsp. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of IL12. Cancer Res 2000; 60: 1111-1116.
59. Shigehera K, Shijubo N, Ohmichi M i wsp. IL-12 and IL-18 are increased and stimulated INFγ production in sarcoid lungs. J Immunol 2001; 166; 642-649.
60. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Schock 1995; 4, 155-160.
61. Moore BB, Keane MP, Addison ChL, Arenberrg DA, Streiter RM. CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J Investig Med 1998; 46: 113-120.
62. Arenberrg DA, Kunkel SL, Polverini PJ i wsp. Interferon-γ- inducibble protein 10 (IP-10) is an angiostatic factor that inhibits human nonsmalll cell lung cancer tumorigenesis and spontaneous matastases. J Exp Med 1996; 184: 981-992.
63. O'Reilly M, Pirie-Sphephard S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the Serpin antithrombin. Science 1999; 285: 1926-1931.
64. Norrby K. Heparin and angiogenesis: a low-molecular-weight fracfion inhibits and high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 1993; 23 (Suppl 1): 141-149.